ManageChatDiscover
178455

The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Anti-cancer Immunotherapy

Abstract

Background: Periampullary cancers constitute about 5% of gastrointestinal malignancies. They are comprised of tumors of diverse origins and are generally subdivided into pancreatic and non-pancreatic carcinomas. Immune checkpoint regulators, cytotoxic T-lymphocyte antigen 4 (CTLA-4), and the programmed cell death ligand-1 (PDL-1) have emerged as promising new targets for cancer therapeutics. Aim: This study aims to determine the possible role of immune checkpoint inhibitors PDL-1 and CTLA-4 in periampullary carcinoma of pancreatic and non-pancreatic adenocarcinoma subtypes, in an attempt to investigate the possible introduction of their related immunotherapy in the management of these tumors. Materials and Methods: Expression of immune inhibitory molecules was examined by immunohistochemistry in 40 cases including (20) pancreatic adenocarcinoma and (20) non-pancreatic adenocarcinoma. The association between markers and clinicopathological parameters was evaluated. Results: Statistically significant differences in the immunoexpression of both CTLA-4 and PDL-1 in the two studied groups were noticed with higher expression in non-pancreatic adenocarcinoma in relation to pancreatic adenocarcinoma (P=0.004, P=0.008) respectively. PDL-1 expression was positive in 15% and 55% of pancreatic and non-pancreatic adenocarcinoma cases, respectively with a significant correlation with lymph nodes metastasis in non-pancreatic adenocarcinoma cases. CTLA-4 was positive in 20% of pancreatic carcinoma with a significant correlation with lymph node metastasis, perineural invasion and T stage. In non-pancreatic periampullary adenocarcinoma, CTLA-4 was positive in 65% of cases with a significant association with lymph nodes metastasis and T stage. Conclusions: Immunotherapy using anti-PDL-1 and CTLA-4 are proposed as a novel promising management tool in non-pancreatic periampullary adenocarcinoma not in pancreatic adenocarcinomas.

DOI

10.21608/jcbr.2021.56525.1108

Keywords

CTLA-4, non-pancreatic periampullary adenocarcinoma, Pancreatic adenocarcinoma, PDL-1

Authors

First Name

Noha

Last Name

El-Anwar

MiddleName

Mohamed

Affiliation

Pathology department, faculty of medicine Tanta University Pathology department, Armed Forces College of Medicine

Email

nohaelanwar@gmail.com

City

Tanta

Orcid

0000-0002-7961-7577

First Name

Reham

Last Name

El Nemr

MiddleName

Shehab

Affiliation

Pathology Department, Faculty of Medicine, Fayoum University and Pathology Department Armed Forces College of Medicine

Email

rehamelnemr@yahoo.com

City

-

Orcid

-

Volume

5

Article Issue

2

Related Issue

24923

Issue Date

2021-06-01

Receive Date

2021-01-04

Publish Date

2021-06-01

Page Start

143

Page End

152

Print ISSN

2682-261X

Online ISSN

2682-2628

Article File

JCBR_Volume 5_Issue 2_Pages 143-152.pdf

PDF . 8.0MB

Link

https://jcbr.journals.ekb.eg/article_178455.html

Detail API

https://jcbr.journals.ekb.eg/service?article_code=178455

Order

13

Type

Original Article

Type Code

885

Publication Type

Journal

Publication Title

International Journal of Cancer and Biomedical Research

Publication Link

https://jcbr.journals.ekb.eg/

MainTitle

The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

Details

Type

Article

Created At

22 Jan 2023